Baiocchi Otávio C G, Colleoni Gisele W B, Caballero Otávia L, Vettore André L, Bulgarelli Adriana, Dalbone Maria Aparecida, Granato Celso F H, Franco Marcello F, Pestana José O M
Hematology and Transfusion Medicine Service, Universidade Federal de São Paulo, UNIFESP/EPM, São Paulo, Brazil.
Leuk Lymphoma. 2005 Apr;46(4):533-9. doi: 10.1080/10428190400027837.
The possible correlation among Epstein-Barr virus (EBV) load, interleukin-6 (IL-6) and interleukin-10 (IL-10) levels has become an attractive issue and can provide a useful tool for diagnosis and monitoring of patients at risk for post-transplant lymphoproliferative disease (PTLD) development. At the time of diagnosis of PTLD, 11 patients were prospectively enrolled and 55 nested controls were selected from a 1800 renal transplant cohort. Real-time polymerase chain reaction (PCR) was used to quantify EBV load in peripheral blood mononuclear cells (PBMC). Serum IL-6 and IL-10 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The median EBV load of PTLD cases was 17400 copies/10(6) PBMC, statistically different from controls (P=0.001). The median IL-6 level of PTLD cases was not different from controls (P=0.079). However, median IL-10 levels showed a significant difference in both groups (P < or = 0.001). The receiver-operating characteristic (ROC) curve analysis was applied to estimate the IL-10 cut-off value predictive of PTLD development. We found that 73.5 pg/ml has high sensitivity (1.00) and specificity (0.85). Also, Pearson's analysis showed a strong correlation between EBV load and serum IL-10 concentration (P < or = 0.001). This nested case-control study demonstrates that EBV load at diagnosis of PTLD correlates with IL-10 levels, and that monitoring of IL-10 can provide a less expensive and less time-consuming tool for PTLD diagnosis and close follow-up of patients at risk. Furthermore, we were able to define a cut-off value of IL-10 mostly predictive of PTLD development in this cohort. Our data suggest that serial measurements prior to PTLD development must be carried out to validate our hypothesis.
爱泼斯坦-巴尔病毒(EBV)载量、白细胞介素-6(IL-6)和白细胞介素-10(IL-10)水平之间可能存在的相关性已成为一个引人关注的问题,并且可为移植后淋巴增生性疾病(PTLD)发生风险患者的诊断和监测提供有用工具。在PTLD诊断时,前瞻性纳入了11例患者,并从1800例肾移植队列中选取了55例配对对照。采用实时聚合酶链反应(PCR)定量外周血单个核细胞(PBMC)中的EBV载量。使用酶联免疫吸附测定(ELISA)测定血清IL-6和IL-10水平。PTLD病例的EBV载量中位数为17400拷贝/10(6) PBMC,与对照组相比有统计学差异(P=0.001)。PTLD病例的IL-6水平中位数与对照组无差异(P=0.079)。然而,两组的IL-10水平中位数显示出显著差异(P≤0.001)。应用受试者工作特征(ROC)曲线分析来估计预测PTLD发生的IL-10临界值。我们发现73.5 pg/ml具有高敏感性(1.00)和特异性(0.85)。此外,Pearson分析显示EBV载量与血清IL-10浓度之间存在强相关性(P≤0.001)。这项配对病例对照研究表明,PTLD诊断时的EBV载量与IL-10水平相关,并且监测IL-10可为PTLD诊断和对有风险患者的密切随访提供一种成本较低且耗时较少的工具。此外,我们能够确定该队列中最能预测PTLD发生的IL-10临界值。我们的数据表明,必须在PTLD发生之前进行系列测量以验证我们的假设。